Status:
COMPLETED
Efficacy of COVID-19 Vaccination in Patientstreated With Anti-CD20 for Follicular Lymphoma or Mantle Cell Lymphoma
Lead Sponsor:
Centre Henri Becquerel
Conditions:
Follicular Lymphoma
Mantle Cell Lymphoma
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
The anti-CD20 monoclonal antibodies, rituximab (R) and obinutuzumab (G), are used as standard maintenance therapy every 2 months for 2 to 3 years in patients with follicular lymphoma (FL) or mantle ce...
Eligibility Criteria
Inclusion
- Age superior to 18 years old
- Patient undergoing maintenance treatment for Mantle Cell Lymphoma or Follicular Lymphoma treated with rituximab or obinutuzumab in complete remission or stable disease between injection #1 and injection #13 or 19 (end of second year or third year)
- Inform consent signed
Exclusion
- Documented history of SARS-Cov-2 infection less than 3 months old
- Progressive lymphoma
- Contraindication SARS-Cov-2 vaccination (allergy)
- Refusal of SARS-CoV-2 vaccination
- Patient who has been off rituximab or obinutuzumab therapy for more than 6 months
- Patient not covered by health system
- Pregnant or nursing woman
Key Trial Info
Start Date :
May 21 2021
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
June 27 2022
Estimated Enrollment :
20 Patients enrolled
Trial Details
Trial ID
NCT04918940
Start Date
May 21 2021
End Date
June 27 2022
Last Update
December 23 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Centre Henri Becquerel
Rouen, France